Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 266

1.

Should a Multigene Signature be Used in all Luminal Early Breast Cancers.

Hajjaji N, Robin YM, Bonneterre J.

Front Oncol. 2019 Jun 4;9:454. doi: 10.3389/fonc.2019.00454. eCollection 2019.

2.

Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.

Montemurro F, Ellis P, Anton A, Wuerstlein R, Delaloge S, Bonneterre J, Quenel-Tueux N, Linn SC, Irahara N, Donica M, Lindegger N, Barrios CH.

Eur J Cancer. 2019 Mar;109:92-102. doi: 10.1016/j.ejca.2018.12.022. Epub 2019 Jan 29.

3.

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.

Cottu PH, Bonneterre J, Varga A, Campone M, Leary A, Floquet A, Berton-Rigaud D, Sablin MP, Lesoin A, Rezai K, Lokiec FM, Lhomme C, Bosq J, Bexon AS, Gilles EM, Proniuk S, Dieras V, Jackson DM, Zukiwski A, Italiano A.

PLoS One. 2018 Oct 10;13(10):e0204973. doi: 10.1371/journal.pone.0204973. eCollection 2018.

4.

French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.

Briot K, Paccou J, Beuzeboc P, Bonneterre J, Bouvard B, Confavreux CB, Cormier C, Cortet B, Hannoun-Lévi JM, Hennequin C, Javier RM, Lespessailles E, Mayeur D, Mongiat Artus P, Vieillard MH, Debiais F.

Joint Bone Spine. 2019 Jan;86(1):21-28. doi: 10.1016/j.jbspin.2018.09.017. Epub 2018 Oct 1.

PMID:
30287350
5.

[Neuroendocrine tumors of the breast: Myth or reality? A systematic review].

Cheymol C, Abramovici O, Do Cao C, Dumont A, Robin YM, El Hajbi F, Dansin E, Bonneterre J, Lauridant G.

Bull Cancer. 2018 Apr;105(4):431-439. doi: 10.1016/j.bulcan.2018.01.013. Epub 2018 Mar 19. Review. French.

PMID:
29567279
6.

Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients.

Jobard E, Trédan O, Bachelot T, Vigneron AM, Aït-Oukhatar CM, Arnedos M, Rios M, Bonneterre J, Diéras V, Jimenez M, Merlin JL, Campone M, Elena-Herrmann B.

Oncotarget. 2017 Jun 28;8(48):83570-83584. doi: 10.18632/oncotarget.18784. eCollection 2017 Oct 13.

7.

Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.

Le Rhun E, Bertrand N, Dumont A, Tresch E, Le Deley MC, Mailliez A, Preusser M, Weller M, Revillion F, Bonneterre J.

Eur J Cancer. 2017 Dec;87:189-198. doi: 10.1016/j.ejca.2017.10.006. Epub 2017 Nov 2.

8.

Chemical meningitis related to intra-CSF liposomal cytarabine.

Durand B, Zairi F, Boulanger T, Bonneterre J, Mortier L, Le Rhun E.

CNS Oncol. 2017 Oct;6(4):261-267. doi: 10.2217/cns-2016-0046. Epub 2017 Oct 23.

9.

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G.

PLoS One. 2017 May 8;12(5):e0175998. doi: 10.1371/journal.pone.0175998. eCollection 2017.

10.

Increased risk of brain metastases in women with breast cancer and p16 expression in metastatic lymph-nodes.

Furet E, El Bouchtaoui M, Feugeas JP, Miquel C, Leboeuf C, Beytout C, Bertheau P, Le Rhun E, Bonneterre J, Janin A, Bousquet G.

Oncotarget. 2017 Jun 6;8(23):37332-37341. doi: 10.18632/oncotarget.16953.

11.

Structural basis for chemokine recognition by a G protein-coupled receptor and implications for receptor activation.

Ziarek JJ, Kleist AB, London N, Raveh B, Montpas N, Bonneterre J, St-Onge G, DiCosmo-Ponticello CJ, Koplinski CA, Roy I, Stephens B, Thelen S, Veldkamp CT, Coffman FD, Cohen MC, Dwinell MB, Thelen M, Peterson FC, Heveker N, Volkman BF.

Sci Signal. 2017 Mar 21;10(471). pii: eaah5756. doi: 10.1126/scisignal.aah5756.

12.

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.

Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, Levy C, Ferrero JM, Romieu G, Bonneterre J, Lerebours F, Bachelot T, Kerbrat P, Campone M, Eymard JC, Mouret-Reynier MA, Gligorov J, Hardy-Bessard AC, Lortholary A, Soulie P, Boher JM, Proudhon C, Charafe-Jaufret E, Lemonnier J, Bertucci F, Viens P.

Ann Oncol. 2017 Jan 1;28(1):103-109. doi: 10.1093/annonc/mdw535.

PMID:
28177480
13.

Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort.

Bonneterre J, Bosq J, Jamme P, Valent A, Gilles EM, Zukiwski AA, Fuqua SA, Lange CA, O'Shaughnessy J.

ESMO Open. 2016 Aug 22;1(4):e000072. eCollection 2016.

14.

High expression levels of egfl7 correlate with low endothelial cell activation in peritumoral vessels of human breast cancer.

Pannier D, Philippin-Lauridant G, Baranzelli MC, Bertin D, Bogart E, Delprat V, Villain G, Mattot V, Bonneterre J, Soncin F.

Oncol Lett. 2016 Aug;12(2):1422-1428. Epub 2016 Jun 28.

15.

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

Bertucci F, Fekih M, Autret A, Petit T, Dalenc F, Levy C, Romieu G, Bonneterre J, Ferrero JM, Kerbrat P, Soulie P, Mouret-Reynier MA, Bachelot T, Lerebours F, Eymard JC, Deblock M, Lortholary A, Hardy-Bessard AC, Barthelemy P, Bonnefoi H, Charafe-Jauffret E, Bidard FC, Viens P, Lemonnier J, Pierga JY.

Lancet Oncol. 2016 May;17(5):600-11. doi: 10.1016/S1470-2045(16)00011-5. Epub 2016 Mar 28.

PMID:
27032301
16.

Analysis of Arrestin Recruitment to Chemokine Receptors by Bioluminescence Resonance Energy Transfer.

Bonneterre J, Montpas N, Boularan C, Galés C, Heveker N.

Methods Enzymol. 2016;570:131-53. doi: 10.1016/bs.mie.2015.09.003. Epub 2015 Nov 29.

PMID:
26921945
17.

Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study.

Bonneterre J, Prat A, Galván P, Morel P, Giard S.

Curr Med Res Opin. 2016 May;32(5):835-9. doi: 10.1185/03007995.2016.1146664. Epub 2016 Feb 12.

PMID:
26809116
18.

ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors.

Dumont A, Pannier D, Ducoulombier A, Tresch E, Chen J, Kramar A, Révillion F, Peyrat JP, Bonneterre J.

Springerplus. 2015 Jul 7;4:327. doi: 10.1186/s40064-015-1053-0. eCollection 2015.

19.

A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.

Le Rhun E, Delbeuck X, Lefeuvre-Plesse C, Kramar A, Skrobala E, Pasquier F, Bonneterre J.

Breast Cancer Res Treat. 2015 Aug;152(3):569-80. doi: 10.1007/s10549-015-3493-1. Epub 2015 Jul 11.

PMID:
26160250
20.

Development of a technique to detect the activated form of the progesterone receptor and correlation with clinical and histopathological characteristics of endometrioid adenocarcinoma of the uterine corpus.

Bonneterre J, Hutt E, Bosq J, Graham JD, Powell MA, Leblanc E, Fujiwara K, Herzog TJ, Coleman RL, Clarke CL, Gilles EM, Zukiwski AA, Monk BJ.

Gynecol Oncol. 2015 Sep;138(3):663-7. doi: 10.1016/j.ygyno.2015.06.037. Epub 2015 Jul 2.

PMID:
26142884
21.

Prolonged Response and Restoration of Functional Independence with Bevacizumab plus Vinorelbine as Third-Line Treatment for Breast Cancer-Related Leptomeningeal Metastases.

Le Rhun E, Taillibert S, Boulanger T, Zairi F, Bonneterre J, Chamberlain MC.

Case Rep Oncol. 2015 Feb 12;8(1):72-7. doi: 10.1159/000375293. eCollection 2015 Jan-Apr.

22.

[Systemic treatment of brain metastases from breast cancer].

Taillibert S, Conforti R, Bonneterre J, Bachelot T, Le Rhun E, Bernard-Marty C.

Cancer Radiother. 2015 Feb;19(1):36-42. doi: 10.1016/j.canrad.2014.12.003. Epub 2015 Feb 7. Review. French.

PMID:
25662600
23.

Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.

Pierga JY, Petit T, Lévy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Bonneterre J, Hernandez J, Bidard FC, Viens P.

Clin Cancer Res. 2015 Mar 15;21(6):1298-304. doi: 10.1158/1078-0432.CCR-14-1705. Epub 2014 Dec 23.

24.

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine.

Mailliez A, Servent V, Bonneterre J, Le Rhun E.

Case Rep Oncol. 2014 Aug 7;7(2):555-9. doi: 10.1159/000365747. eCollection 2014 May.

25.

Decrease social inequalities return-to-work: development and design of a randomised controlled trial among women with breast cancer.

Vidor C, Leroyer A, Christophe V, Seillier M, Foncel J, Van de Maële J, Bonneterre J, Fantoni S.

BMC Cancer. 2014 Apr 17;14:267. doi: 10.1186/1471-2407-14-267.

26.

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).

Awada A, Bondarenko IN, Bonneterre J, Nowara E, Ferrero JM, Bakshi AV, Wilke C, Piccart M; CT4002 study group.

Ann Oncol. 2014 Apr;25(4):824-31. doi: 10.1093/annonc/mdu025.

PMID:
24667715
27.

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, Lacroix-Triki M, Lacroix L, Cohen P, Gentien D, Adélaide J, Dalenc F, Goncalves A, Levy C, Ferrero JM, Bonneterre J, Lefeuvre C, Jimenez M, Filleron T, Bonnefoi H.

Lancet Oncol. 2014 Mar;15(3):267-74. doi: 10.1016/S1470-2045(13)70611-9. Epub 2014 Feb 7.

PMID:
24508104
28.

CSF CA 15-3 in breast cancer-related leptomeningeal metastases.

Le Rhun E, Kramar A, Salingue S, Girot M, Rodrigues I, Mailliez A, Zairi F, Bakhache E, Robin YM, Taillibert S, Dubois F, Bonneterre J, Chamberlain MC.

J Neurooncol. 2014 Mar;117(1):117-24. doi: 10.1007/s11060-014-1361-1. Epub 2014 Jan 28.

PMID:
24469852
29.

[What do clinicians do with the results of the systematic staging imaging at the time of the breast cancer diagnosis?].

Turpin A, Mailliez A, Vennin P, Bonneterre J.

Gynecol Obstet Fertil. 2014 May;42(5):325-30. doi: 10.1016/j.gyobfe.2013.11.006. Epub 2014 Jan 7. French.

PMID:
24411340
30.

Salvage intracerebrospinal fluid thiotepa in breast cancer-related leptomeningeal metastases: a retrospective case series.

Le Rhun E, Taillibert S, Devos P, Zairi F, Turpin A, Rodrigues I, Cazin JL, Pierret MF, André C, Dubois F, Bonneterre J, Chamberlain MC.

Anticancer Drugs. 2013 Nov;24(10):1093-7. doi: 10.1097/CAD.0000000000000010.

PMID:
23962903
31.

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

Martin M, Bonneterre J, Geyer CE Jr, Ito Y, Ro J, Lang I, Kim SB, Germa C, Vermette J, Wang K, Wang K, Awada A.

Eur J Cancer. 2013 Dec;49(18):3763-72. doi: 10.1016/j.ejca.2013.07.142. Epub 2013 Aug 15.

PMID:
23953056
32.

Prolonged survival of patients with breast cancer-related leptomeningeal metastases.

Le Rhun E, Taillibert S, Zairi F, Pannier D, Boulanger T, Andre C, Cazin JL, Dubois F, Bonneterre J, Chamberlain MC.

Anticancer Res. 2013 May;33(5):2057-63.

PMID:
23645756
33.

Results and consequence of the systematic staging imaging at the time of the breast cancer diagnosis.

Mailliez A, Turpin A, Vennin P, Bonneterre J.

Breast. 2013 Aug;22(4):555. doi: 10.1016/j.breast.2013.03.007. Epub 2013 Apr 18. No abstract available.

PMID:
23602423
34.

A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer.

Le Rhun E, Taillibert S, Zairi F, Kotecki N, Devos P, Mailliez A, Servent V, Vanlemmens L, Vennin P, Boulanger T, Baranzelli MC, André C, Marliot G, Cazin JL, Dubois F, Assaker R, Bonneterre J, Chamberlain MC.

J Neurooncol. 2013 May;113(1):83-92. doi: 10.1007/s11060-013-1092-8. Epub 2013 Mar 1.

PMID:
23456656
35.

Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer.

Philippin-Lauridant G, Baranzelli MC, Samson C, Fournier C, Pinte S, Mattot V, Bonneterre J, Soncin F.

Int J Oncol. 2013 Apr;42(4):1367-75. doi: 10.3892/ijo.2013.1820. Epub 2013 Feb 8.

PMID:
23404186
36.

[Systemic treatment of brain metastases from breast cancer: cytotoxic chemotherapy and targeted therapies].

Bachelot T, Le Rhun E, Labidi-Gally I, Heudel P, Gilabert M, Bonneterre J, Pierga JY, Gonçalves A.

Bull Cancer. 2013 Jan 1;100(1):7-14. doi: 10.1684/bdc.2012.1676. Review. French.

37.

[Ki67 in young patients with breast cancer].

Vasseur F, Baranzelli MC, Fournier C, Bonneterre J.

Gynecol Obstet Fertil. 2013 Jan;41(1):16-9. doi: 10.1016/j.gyobfe.2012.11.005. Epub 2013 Jan 1. French.

PMID:
23286956
38.

Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients.

Pape E, Desmedt E, Zairi F, Baranzelli MC, Dziwniel V, Dubois F, Bonneterre J, Mortier L, Le Rhun E.

In Vivo. 2012 Nov-Dec;26(6):1079-86.

PMID:
23160697
39.

Role of the investigator in phase 1 trials of anticancer drugs.

Penel N, Adenis A, Bonneterre J.

Lancet Oncol. 2012 Dec;13(12):1177-9. doi: 10.1016/S1470-2045(12)70502-8. Epub 2012 Nov 13. No abstract available.

PMID:
23153505
40.

Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis.

Le Rhun E, Massin F, Tu Q, Bonneterre J, Bittencourt Mde C, Faure GC.

BMC Clin Pathol. 2012 Nov 12;12:21. doi: 10.1186/1472-6890-12-21.

41.

Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.

Bonneterre J, Révillion F, Desauw C, Blot E, Kramar A, Fournier C, Hornez L, Peyrat JP.

Oncol Rep. 2013 Jan;29(1):355-61. doi: 10.3892/or.2012.2090. Epub 2012 Oct 19.

PMID:
23117275
42.

Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.

Cousin S, Le Rhun E, Mailliez A, Fournier C, Bonneterre J.

Bull Cancer. 2012 Jul-Aug;99(7-8):75-80. doi: 10.1684/bdc.2012.1607.

PMID:
22713627
43.

Relationships between progesterone receptor isoforms and the HER/ErbB receptors and ligands network in 299 primary breast cancers.

Lindet C, Révillion F, Lhotellier V, Hornez L, Peyrat JP, Bonneterre J.

Int J Biol Markers. 2012 Jul 19;27(2):e111-7. doi: 10.5301/JBM.2012.9198. Review.

PMID:
22505232
44.

The sequential use of endocrine treatment for advanced breast cancer: where are we?

Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C, Robertson JF.

Ann Oncol. 2012 Jun;23(6):1378-86. doi: 10.1093/annonc/mdr593. Epub 2012 Feb 8. Review.

45.

The quality of life of young women with nonmetastatic breast cancer and their partners': specific needs require development of specific questionnaires for each of them.

Vanlemmens L, Christophe V, Fournier E, Dauchy S, Boinon D, Toudic-Emily F, Duffour B, Machavoine JL, Reich M, Bonneterre J, Domont J, Kaci FA, Antoine P.

Breast J. 2012 Mar-Apr;18(2):182-4. doi: 10.1111/j.1524-4741.2011.01218.x. Epub 2012 Jan 29. No abstract available.

PMID:
22284212
46.

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.

Brain E, Isambert N, Dalenc F, Diéras V, Bonneterre J, Rezai K, Jimenez M, Mefti-Lacheraf F, Cottura E, Tresca P, Vanlemmens L, Mahier-Aït Oukhatar C, Lokiec F, Fumoleau P.

Br J Cancer. 2012 Feb 14;106(4):673-7. doi: 10.1038/bjc.2011.591. Epub 2012 Jan 12.

47.

A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.

Campone M, Isambert N, Bourbouloux E, Roché H, Bonneterre J, Milano G, Fumoleau P.

Cancer Chemother Pharmacol. 2012 Apr;69(4):871-9. doi: 10.1007/s00280-011-1767-9. Epub 2011 Nov 2.

PMID:
22045498
48.

Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation.

Delfortrie S, Pinte S, Mattot V, Samson C, Villain G, Caetano B, Lauridant-Philippin G, Baranzelli MC, Bonneterre J, Trottein F, Faveeuw C, Soncin F.

Cancer Res. 2011 Dec 1;71(23):7176-86. doi: 10.1158/0008-5472.CAN-11-1301. Epub 2011 Oct 28.

49.

Predictive value of neoadjuvant chemotherapy failure in breast cancer using FDG-PET after the first course.

Kolesnikov-Gauthier H, Vanlemmens L, Baranzelli MC, Vennin P, Servent V, Fournier C, Carpentier P, Bonneterre J.

Breast Cancer Res Treat. 2012 Jan;131(2):517-25. doi: 10.1007/s10549-011-1832-4. Epub 2011 Oct 26.

PMID:
22037787
50.

Is adjuvant chemotherapy useful in lobular breast cancer patients?

Liem X, Baranzelli MC, Penel N, Giard S, Bonneterre J.

Ann Oncol. 2011 Nov;22(11):2532-3. doi: 10.1093/annonc/mdr312. Epub 2011 Jun 23. No abstract available.

PMID:
21700733

Supplemental Content

Loading ...
Support Center